The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2

Metastatic gastric carcinoma is a mortal disease with a median survival of barely 10 months. An approximate 20% of the cases overexpress HER2, and among them, the combination of chemotherapy with trastuzumab is actually the first-line palliative treatment. However, after progression, sequential stra...

Descripción completa

Detalles Bibliográficos
Autores principales: Saavedra Santa Gadea, Omar, Valdivia García, Francisco José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567011/
https://www.ncbi.nlm.nih.gov/pubmed/28868025
http://dx.doi.org/10.1159/000478003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567011/
https://www.ncbi.nlm.nih.gov/pubmed/28868025
http://dx.doi.org/10.1159/000478003

Ejemplares similares